Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification
Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients
Sponsor: Laboratorios Sophia S.A de C.V.
This PHASE2 trial investigates Cataract and Phacoemulsification Cataract Surgery and is currently completed. Laboratorios Sophia S.A de C.V. leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Laboratorios Sophia S.A de C.V.
For direct contact, visit the study record on ClinicalTrials.gov .